Nonetheless, T-cell stimulation with agonistic α-CD40 mAbs plus gemcitabine and nab-paclitaxel induced tumor regression and increased survival [56], suggesting that CD40-mediated induction of the T-cell response can overcome PDA resistance to α-CTLA4 immunotherapy (see below). Here, CTLA4 is linked to neoplasm.